Abbott Laboratories (ABT)vsNeuropace Inc (NPCE)
ABT
Abbott Laboratories
$101.95
-1.36%
HEALTHCARE · Cap: $176.41B
NPCE
Neuropace Inc
$14.04
+1.23%
HEALTHCARE · Cap: $511.43M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 43440% more annual revenue ($46.59B vs $106.99M). ABT leads profitability with a 11.7% profit margin vs -17.9%. ABT earns a higher WallStSmart Score of 54/100 (C-).
ABT
Buy54
out of 100
Grade: C-
NPCE
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$74.13
Current Price
$101.95
$27.82 premium
Margin of Safety
-17.2%
Fair Value
$12.42
Current Price
$14.04
$1.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
17.1% revenue growth
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 40.1x book value
ROE of -160.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : NPCE
The strongest argument for NPCE centers on Revenue Growth. Revenue growth of 17.1% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 5.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABT profiles as a value stock while NPCE is a growth play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.95 — expect wider price swings.
NPCE is growing revenue faster at 17.1% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (54/100 vs 27/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?